Skip to main content
Top
Published in: Journal of Translational Medicine 1/2018

Open Access 01-12-2018 | Research

Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer

Authors: Fangmeng Fu, Wenhui Guo, Yuxiang Lin, Bangwei Zeng, Wei Qiu, Meng Huang, Chuan Wang

Published in: Journal of Translational Medicine | Issue 1/2018

Login to get access

Abstract

Background

Limited evidence suggests that inherited predisposing risk variants might affect the disease outcome. In this study, we analyzed the effect of genome-wide association studies—identified breast cancer-risk single nucleotide polymorphisms on survival of early-stage breast cancer patients in a Chinese population.

Methods

This retrospective study investigated the relationship between 21 GWAS-identified breast cancer-risk single nucleotide polymorphisms and the outcome of 1177 early stage breast cancer patients with a long median follow-up time of 174 months. Cox proportional hazards regression models were used to estimate the hazard ratios and their 95% confidence intervals. Primary endpoints were breast cancer special survival and overall survival while secondary endpoints were invasive disease free survival and distant disease free survival.

Results

Multivariate survival analysis showed only the rs2046210 GA genotype significantly decreased the risk of recurrence and death for early stage breast cancer. After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer. Importantly, all three single-nucleotide polymorphisms, rs889312, rs4951011 and rs9485372 had remarkable effects on survival of luminal B EBC, either individually or synergistically. Furthermore, statistically significant multiplicative interactions were found between rs4415084 and age at diagnosis and between rs3803662 and tumor grade.

Conclusions

Our results demonstrate that breast cancer risk susceptibility loci identified by GWAS may influence the outcome of early stage breast cancer patients’ depending on intrinsic tumor subtypes in Chinese women.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
2.
go back to reference Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15:e279–89.CrossRefPubMed Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15:e279–89.CrossRefPubMed
4.
go back to reference Świerniak M, Wójcicka A, Czetwertyńska M, Długosińska J, Stachlewska E, Gierlikowski W, Kot A, Górnicka B, Koperski Ł, Bogdańska M, Wiechno W, Jażdżewski K. Association between GWAS-derived rs966423 genetic variant and overall mortality in patients with differentiated thyroid cancer. Clin Cancer Res. 2016;22:1111–9.CrossRefPubMed Świerniak M, Wójcicka A, Czetwertyńska M, Długosińska J, Stachlewska E, Gierlikowski W, Kot A, Górnicka B, Koperski Ł, Bogdańska M, Wiechno W, Jażdżewski K. Association between GWAS-derived rs966423 genetic variant and overall mortality in patients with differentiated thyroid cancer. Clin Cancer Res. 2016;22:1111–9.CrossRefPubMed
5.
go back to reference Kang BW, Jeon HS, Chae YS, Lee SJ, Park JY, Choi JE, Park JS, Choi GS, Kim JG. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer. PLoS ONE. 2015;10:e0119649.CrossRefPubMedPubMedCentral Kang BW, Jeon HS, Chae YS, Lee SJ, Park JY, Choi JE, Park JS, Choi GS, Kim JG. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer. PLoS ONE. 2015;10:e0119649.CrossRefPubMedPubMedCentral
6.
go back to reference Barrdahl M, Canzian F, Lindström S, Shui I, Black A, Hoover RN, Ziegler RG, Buring JE, Chanock SJ, Diver WR, Gapstur SM, Gaudet MM, Giles GG, Haiman C, Henderson BE, Hankinson S, Hunter DJ, Joshi AD, Kraft P, Lee IM, Le Marchand L, Milne RL, Southey MC, Willett W, Gunter M, Panico S, Sund M, Weiderpass E, Sánchez MJ, Overvad K, Dossus L, Peeters PH, Khaw KT, Trichopoulos D, Kaaks R, Campa D. Association of breast cancer risk loci with breast cancer survival. Int J Cancer. 2015;137:2837–45.CrossRefPubMedPubMedCentral Barrdahl M, Canzian F, Lindström S, Shui I, Black A, Hoover RN, Ziegler RG, Buring JE, Chanock SJ, Diver WR, Gapstur SM, Gaudet MM, Giles GG, Haiman C, Henderson BE, Hankinson S, Hunter DJ, Joshi AD, Kraft P, Lee IM, Le Marchand L, Milne RL, Southey MC, Willett W, Gunter M, Panico S, Sund M, Weiderpass E, Sánchez MJ, Overvad K, Dossus L, Peeters PH, Khaw KT, Trichopoulos D, Kaaks R, Campa D. Association of breast cancer risk loci with breast cancer survival. Int J Cancer. 2015;137:2837–45.CrossRefPubMedPubMedCentral
7.
go back to reference Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013;18:493–500.CrossRefPubMedPubMedCentral Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013;18:493–500.CrossRefPubMedPubMedCentral
8.
go back to reference Cai Q, Zhang B, Sung H, et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014;46:886–90.CrossRefPubMedPubMedCentral Cai Q, Zhang B, Sung H, et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014;46:886–90.CrossRefPubMedPubMedCentral
9.
go back to reference Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS ONE. 2013;8:e76463.CrossRefPubMedPubMedCentral Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS ONE. 2013;8:e76463.CrossRefPubMedPubMedCentral
10.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
11.
go back to reference Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentral
12.
go back to reference Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015;26:873–9.CrossRefPubMed Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015;26:873–9.CrossRefPubMed
13.
go back to reference Xu Y, Chen M, Liu C, Zhang X, Li W, Cheng H, Zhu J, Zhang M, Chen Z, Zhang B. Association study confirmed three breast cancer-specific molecular subtype-associated susceptibility loci in Chinese Han Women. Oncologist. 2017;22:890–4.CrossRefPubMedPubMedCentral Xu Y, Chen M, Liu C, Zhang X, Li W, Cheng H, Zhu J, Zhang M, Chen Z, Zhang B. Association study confirmed three breast cancer-specific molecular subtype-associated susceptibility loci in Chinese Han Women. Oncologist. 2017;22:890–4.CrossRefPubMedPubMedCentral
15.
go back to reference Sapkota Y. Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res. 2014;144:77–91.CrossRefPubMed Sapkota Y. Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res. 2014;144:77–91.CrossRefPubMed
16.
go back to reference Song N, Choi JY, Sung H, Jeon S, Chung S, Park SK, Han W, Lee JW, Kim MK, Lee JY, Yoo KY, Han BG, Ahn SH, Noh DY, Kang D. Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes. PLoS ONE. 2015;10:e0122413.CrossRefPubMedPubMedCentral Song N, Choi JY, Sung H, Jeon S, Chung S, Park SK, Han W, Lee JW, Kim MK, Lee JY, Yoo KY, Han BG, Ahn SH, Noh DY, Kang D. Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes. PLoS ONE. 2015;10:e0122413.CrossRefPubMedPubMedCentral
17.
go back to reference Chan CHT, Munusamy P, Loke SY, Koh GL, Wong ESY, Law HY, Yoon CS, Tan MH, Yap YS, Ang P, Lee ASG. Identification of novel breast cancer risk loci. Cancer Res. 2017;77:5428–37.CrossRefPubMed Chan CHT, Munusamy P, Loke SY, Koh GL, Wong ESY, Law HY, Yoon CS, Tan MH, Yap YS, Ang P, Lee ASG. Identification of novel breast cancer risk loci. Cancer Res. 2017;77:5428–37.CrossRefPubMed
18.
go back to reference Zheng Q, Ye J, Wu H, Yu Q, Cao J. Association between mitogen-activated protein kinase kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case–control studies. PLoS ONE. 2014;9:e90771.CrossRefPubMedPubMedCentral Zheng Q, Ye J, Wu H, Yu Q, Cao J. Association between mitogen-activated protein kinase kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case–control studies. PLoS ONE. 2014;9:e90771.CrossRefPubMedPubMedCentral
19.
go back to reference Wei X, Zhang E, Wang C, Gu D, Shen L, Wang M, Xu Z, Gong W, Tang C, Gao J, Chen J, Zhang Z. A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population. PLoS ONE. 2014;9:e96083.CrossRefPubMedPubMedCentral Wei X, Zhang E, Wang C, Gu D, Shen L, Wang M, Xu Z, Gong W, Tang C, Gao J, Chen J, Zhang Z. A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population. PLoS ONE. 2014;9:e96083.CrossRefPubMedPubMedCentral
20.
go back to reference Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 2017;8:20925–38.PubMedCentralPubMed Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 2017;8:20925–38.PubMedCentralPubMed
21.
go back to reference Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J Biol Chem. 2003;278:1403–6.CrossRefPubMed Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J Biol Chem. 2003;278:1403–6.CrossRefPubMed
22.
go back to reference Chen Y, Fu F, Lin Y, Qiu L, Lu M, Zhang J, Qiu W, Yang P, Wu N, Huang M, Wang C. The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population. Oncotarget. 2016;7:75457–67.PubMedCentralPubMed Chen Y, Fu F, Lin Y, Qiu L, Lu M, Zhang J, Qiu W, Yang P, Wu N, Huang M, Wang C. The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population. Oncotarget. 2016;7:75457–67.PubMedCentralPubMed
23.
go back to reference ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816.CrossRef ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816.CrossRef
24.
go back to reference Ali MA, Younis S, Wallerman O, Gupta R, Andersson L, Sjöblom T. Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proc Natl Acad Sci USA. 2015;112:7743–8.CrossRef Ali MA, Younis S, Wallerman O, Gupta R, Andersson L, Sjöblom T. Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proc Natl Acad Sci USA. 2015;112:7743–8.CrossRef
25.
go back to reference Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefPubMed Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefPubMed
26.
go back to reference Li J, Wang Y, Zhu Y, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Ke J, Gong J, Zhong R, Chang J. Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population. Carcinogenesis. 2017;38:447–54.CrossRefPubMed Li J, Wang Y, Zhu Y, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Ke J, Gong J, Zhong R, Chang J. Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population. Carcinogenesis. 2017;38:447–54.CrossRefPubMed
27.
go back to reference Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M. Targeting of the adaptor protein Tab 2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene. 2012;31:4353–61.CrossRefPubMed Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M. Targeting of the adaptor protein Tab 2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene. 2012;31:4353–61.CrossRefPubMed
28.
go back to reference Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, Abdelhak S, Benhadjayed A, Memmi H, Mathew RA, Aigha II, Gabbouj S, Remadi Y, Chouchane L. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast Cancer Res Treat. 2012;135:715–24.CrossRefPubMedPubMedCentral Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, Abdelhak S, Benhadjayed A, Memmi H, Mathew RA, Aigha II, Gabbouj S, Remadi Y, Chouchane L. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast Cancer Res Treat. 2012;135:715–24.CrossRefPubMedPubMedCentral
Metadata
Title
Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer
Authors
Fangmeng Fu
Wenhui Guo
Yuxiang Lin
Bangwei Zeng
Wei Qiu
Meng Huang
Chuan Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-018-1634-0

Other articles of this Issue 1/2018

Journal of Translational Medicine 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.